InflaRx (IFRX) Revenue Growth (3y) (2021 - 2026)
InflaRx (IFRX) Revenue Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 10.17% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.76% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 77.85% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -25.02% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 42.02% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 59.40% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -37.68% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 76.62% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.80% |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.00% |
| Dec 31, 2025 | 448.80% |
| Sep 30, 2025 | 26.86% |
| Jun 30, 2025 | -85.88% |
| Mar 31, 2025 | 26.84% |
| Dec 31, 2024 | 26.15% |
| Sep 30, 2024 | 29.52% |
| Jun 30, 2024 | -92.59% |
| Mar 31, 2024 | 26.37% |
| Dec 31, 2023 | 26.06% |
| Sep 30, 2023 | 4,876.42% |
| Jun 30, 2023 | -33.30% |
| Mar 31, 2023 | 2,188.26% |
| Dec 31, 2022 | -99.01% |
| Sep 30, 2022 | -38.90% |
| Jun 30, 2022 | -4.54% |
| Mar 31, 2022 | -105.67% |
| Dec 31, 2021 | -10.01% |
| Sep 30, 2021 | 25.85% |
| Jun 30, 2021 | 18.88% |